Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Dec;43(12):2848-54.
doi: 10.1128/AAC.43.12.2848.

Pharmacokinetics of cefepime in patients with thermal burn injury

Affiliations
Clinical Trial

Pharmacokinetics of cefepime in patients with thermal burn injury

C R Bonapace et al. Antimicrob Agents Chemother. 1999 Dec.

Abstract

The pharmacokinetics of cefepime following administration of a single 2-g dose were evaluated for 12 adult patients with thermal burn injury and suspected or documented infection. Serial blood and urine samples for cefepime concentration determination were obtained for 24 h following drug administration. Serum and urine cefepime concentrations were determined by high-performance liquid chromatography and serum concentrations were fit to a two-compartment pharmacokinetic model. Mean (standard deviation [SD]) age, actual body weight (ABW), percent total body surface area burned, and days postburn at the time of study were 41 (13) years, 84 (22) kg, 36 (17)%, and 9 (3) days, respectively. Mean (SD) measured creatinine clearance (CL(CR)), total clearance (CL(T)), renal clearance (CL(R)), alpha phase half-life, beta phase half-life, and volume of distribution at steady state (V(SS)) were 135 (31) ml/min, 8.8 (2.4) liters/h, 8.1 (2.0) liters/h, 0.33 (0.14) h, 2.8 (0.6) h, and 0.43 (0.10) liters/kg ABW, respectively. Cefepime CL(T) and CL(R) in burn patients were similar to previously reported values for healthy volunteers when normalized by CL(CR). Stepwise multiple regression was used to associate CL(T) with CL(CR) and days postburn (r(2) = 0.861), CL(R) with CL(CR) and days postburn (r(2) = 0.773), nonrenal clearance with percent third-degree (% 3 degrees ) burn and albumin concentration (r(2) = 0.550), and V(SS) only with % 3 degrees burn (r(2) = 0.624). Simulated steady-state serum concentrations obtained by using the patients' pharmacokinetic parameters exceeded the susceptibility interpretive standard (breakpoint) of cefepime for at least 60% of the dosing interval with dosing regimens of 1 g every 8 h (q8h), 2 g q8h, and 2 g q12h. Despite differences in pharmacokinetic parameters between our patients and healthy volunteers, it appears that these dosing regimens may be adequate in similar burn patients.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Relationship between CLCR and cefepime CLT. CLT = 0.08810 + 0.9568(CLCR); r2 = 0.575; P = 0.0068.
FIG. 2
FIG. 2
Fitted serum concentration-time profile for each patient after a single 2-g dose of cefepime administered over 0.5 h (patient 4 was omitted due to a 1-h infusion).
FIG. 3
FIG. 3
Simulated steady-state serum concentration-time profiles of cefepime at 1 and 2 g q8h (A) and q12h (B) administered over 0.5 h based on mean pharmacokinetic parameters. Overlaid lines representing possible MICs are for showing T > MIC.

References

    1. Adam D, Zellner P R, Koeppe P, Wesch R. Pharmacokinetics of ticarcillin/clavulanate in severely burned patients. J Antimicrob Chemother. 1989;24(Suppl. B):121–130. - PubMed
    1. Bailie G R, Ackerman B H, Fischer J, Solem L D, Rotschafer J C. Increased vancomycin dosage requirements in young burn patients. J Burn Care Rehabil. 1984;5:376–378.
    1. Barbhaiya R H, Forgue S T, Shyu W C, Papp E A, Pittman K A. High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine. Antimicrob Agents Chemother. 1987;31:55–59. - PMC - PubMed
    1. Barbhaiya R H, Forgue S T, Gleason C R, Knupp C A, Pittman K A, Weidler D J, Martin R R. Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob Agents Chemother. 1990;34:1118–1122. - PMC - PubMed
    1. Barbhaiya R H, Knupp C A, Pittman K A. Effects of age and gender on pharmacokinetics of cefepime. Antimicrob Agents Chemother. 1992;36:1181–1185. - PMC - PubMed

Publication types